Molecular Cancer



Open Access Research

Down-regulation of PPARgammal suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells

Yekaterina Y Zaytseva, Xin Wang, R Chase Southard, Natalie K Wallis and Michael W Kilgore*

Address: Department of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, 800 Rose Street, Room MS-305, Lexington, KY 40536-0298, USA

Email: Yekaterina Y Zaytseva - yyzayt2@email.uky.edu; Xin Wang - xwang3@email.uky.edu; R Chase Southard - rcsout0@email.uky.edu; Natalie K Wallis - nkwall2@email.uky.edu; Michael W Kilgore* - mwkilg0@email.uky.edu

* Corresponding author

Published: 5 December 2008

Molecular Cancer 2008, 7:90 doi:10.1186/1476-4598-7-90

Received: 30 April 2008

Accepted: 5 December 2008

This article is available from: http://www.molecular-cancer.com/content/7/1/90

© 2008 Zaytseva et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Peroxisome proliferator-activated receptor gamma (PPAR γ) is a member of the nuclear hormone receptor superfamily and is highly expressed in many human tumors including breast cancer. PPARy has been identified as a potential target for breast cancer therapy based on the fact that its activation by synthetic ligands affects the differentiation, proliferation, and apoptosis of cancer cells. However, the controversial nature of current studies and disappointing results from clinical trials raise questions about the contribution of PPARy signaling in breast cancer development in the absence of stimulation by exogenous ligands. Recent reports from both in vitro and in vivo studies are inconsistent and suggest that endogenous activation of PPARy plays a much more complex role in initiation and progression of cancer than previously thought.

Results: We have previously demonstrated that an increase in expression of PPARyI in MCF-7 breast cancer cells is driven by a tumor-specific promoter. Myc-associated zinc finger protein (MAZ) was identified as a transcriptional mediator of PPARyI expression in these cells. In this study, using RNA interference (RNAi) to inhibit PPARy I expression directly or via down-regulation of MAZ, we report for the first time that a decrease in PPARyI expression results in reduced cellular proliferation in MCF-7 breast cancer cells. Furthermore, we demonstrate that these changes in proliferation are associated with a significant decrease in cell transition from G₁ to the S phase. Using a dominant-negative mutant of PPARyI, Δ 462, we confirmed that PPARyI acts as a pro-survival factor and showed that this phenomenon is not limited to MCF-7 cells. Finally, we demonstrate that down-regulation of PPARyI expression leads to an induction of apoptosis in MCF-7 cells, confirmed by analyzing Bcl-2 expression and PARP-1 cleavage.

Conclusion: Thus, these findings suggest that an increase in PPARyI signaling observed in breast cancer contributes to an imbalance between proliferation and apoptosis, and may be an important hallmark of breast tumorigenesis. The results presented here also warrant further investigation regarding the use of PPARγ ligands in patients who are predisposed or already diagnosed with breast cancer.

Background

Breast cancer is the most common malignancy and the second leading cause of cancer related death among American women [1]. Despite of the fact that recent research efforts have significantly improved the outcome of breast cancer, the complexity and heterogeneity of this disease still urges the necessity to explore new and more specific drug targets. Peroxisome proliferator-activated receptor gamma (PPARy), a member of the nuclear-hormone receptor family, has shown potential as a therapeutic target for prevention and treatment of breast cancer. PPARy is a ligand-activated transcription factor. There are two isoforms of PPARy protein, PPARy1 and PPARy2, the latter of which has the addition of 30 N'-terminal amino acids as a result of the usage of a different promoter and alternative splicing [2]. PPARy plays an important role in adipocyte differentiation, insulin sensitivity, energy metabolism, immune response, and the development of the nervous system [3-5]. It is predominantly expressed in adipose tissues; although, it is also detected in various tissues such as cardiac and skeletal muscle, intestine, vascular smooth muscle, lung, breast, colon, and prostate [6,7]. Some polyunsaturated fatty acids [8-10] and arachidonic acid metabolites [11] are considered to be the natural ligands of PPARy. Synthetic ligands of PPARy include the thiazolidinedione class of anti-diabetic drugs (TZDs) such as rosiglitazone, pioglitazone, troglitazone [12,13], some non-steroidal anti-inflammatory drugs (NSAID) [14], and non-thiazolidinedione tyrosine [15]. In addition, a ligand-independent mechanism of PPARy activation has also been observed due to altered phosphorylation status of the receptor [16].

Recently, PPARy has emerged as a promising target for cancer therapy based on the fact that its activation by synthetic ligands such as TZDs have been shown to induce cell cycle arrest, apoptosis and differentiation in many human malignancies [17,18]. Several studies have demonstrated that PPARy activation by agonists can promote growth inhibition and apoptosis in both primary and metastatic breast malignancies [19-22]. In addition to the anti-proliferative and pro-apoptotic effects, PPARy ligands have also been reported to inhibit invasion and metastasis of human breast cancer cells [23,24]. However, these results were questioned by several studies that demonstrated the ability of PPARy ligands to elicit anti-tumor effects via PPARy-independent pathways and in the absence of PPARy receptors [25,26]. Moreover, there is a debate that the concentrations of PPARy ligands used in many studies are above the saturation level of the receptor. In fact, Roziglitazone, a widely studied PPARy agonist, has shown to induce opposing effects when used in low versus high doses [27]. Furthermore, PPARy antagonists have also shown anticancer effects in a wide range of epithelial cancer cell lines, usually with greater potency than agonists [28].

Existing data from in vivo studies is also controversial. Recent animal studies have demonstrated that PPARy agonists can prevent mammary carcinogenesis and reduce the development of tumors in nude mice [29]. In contrast, another study has demonstrated an increase in the number of tumors when PPARy ligand was administered [30]. To clarify the controversy arising from the use of pharmacological approaches, several animal studies utilized techniques that allowed evaluation of the consequences of PPARy transactivation in breast cancer independent of exogenous stimulation. Studies which employed a genetic approach to explore the intrinsic role of PPARy signaling have demonstrated that an increase in PPARy signaling accelerates mammary gland tumor development and constitutive over-expression of PPARy increases incidence of breast cancer in mice already susceptible to the disease [31]. This group has also shown that mice heterozygous for a null PPARy mutation develop tumors with the same kinetics as those that carry two functional copies [31]. Furthermore, the ablation of PPARy expression in the mouse mammary gland using a Cre- Lox recombination system has demonstrated that no tumors developed in mammary glands lacking PPARy suggesting that PPARy is not a tumor suppressor [32]. In summary, these observations suggest that reduced PPARy expression does not contribute to the initiation of breast cancer; however, acceleration of PPARy signaling after tumor initiation markedly promotes breast cancer development.

In this study, we have begun to elucidate the functional significance of endogenous PPARy activation in breast cancer using an in vitro model. We have previously reported that PPARy1, not PPARy2, is expressed in normal mammary epithelial cells and breast cancer cell lines [33]. Our lab and others have also demonstrated that the level of PPARy1 expression is significantly higher in breast cancer cell lines as compared to normal epithelial cells [33-36]. In addition, we have shown that a distinct promoter regulates PPARy1 expression in MCF-7 cells and that promoter switching mediates differential PPARy1 expression levels between normal and cancer cells [33]. The Mycassociated zinc finger protein (MAZ) has been identified as a transcriptional mediator of PPARy1 in MCF-7 cells [37]. MAZ is a transcriptional factor that controls the expression of various genes through interactions between GC-rich DNA binding sites within the promoter sequence of target genes and the carboxyl-terminal zinc finger motifs of MAZ [38]. Here, we demonstrated that an increase in expression and endogenous transactivation of PPARy1 in MCF-7 breast cancer cells enhances cell proliferation by accelerating cell transition from G₁ to the S

phase. This data was confirmed using a dominant-negative PPAR γ 1 mutant as an alternative approach to inhibit endogenous activity of PPAR γ 1 in two different cell lines, MCF-7 and T47D. We also found that in the absence of exogenous stimulation high expression of PPAR γ 1 significantly inhibits apoptosis in MCF-7 cells.

Results

PPARyl is highly expressed in breast cancer cell lines

Our previous studies revealed that MAZ is a critical transcriptional regulator of PPARy1 in MCF-7 breast cancer cells [37]. We also showed that both PPARy1 and MAZ are highly expressed in MCF-7 cells as compared to normal mammary epithelial cells (HMEC) and tumor-specific expression of PPARy1 is MAZ dependent [37]. To evaluate expression of PPARy1 within other breast cancer cell lines, whole cell lysates from a panel of eight different breast cancer cell lines originated from heterogeneous tumors (ranging from adenocarcinoma to metastatic ductal carcinoma) were examined by Western blot analysis. HMEC cells were used as a control. Figure 1A shows the representative immunoblot for PPARy1. To demonstrate the reproducibility of these data, statistical analysis of three Western blots was performed (Fig. 1B). The results showed that PPARy1 is expressed at significantly higher level in cancer cell lines as compared to HMEC.

RNAi effect on PPAR γ I expression and activity in MCF-7 breast cancer cell line

As discussed above, evaluation of PPARy1 as a potential breast cancer therapy target revealed the complexity of PPARy1 signaling in cancer. The mechanism of PPARy1 activation during cancer development and the functional role of this event in tumorigenesis still remain unclear. To address these questions and elucidate the role of PPARy1 activation in cancer, we utilized the advantages of shRNA techniques. A set of five shRNAs for each of PPARy or MAZ gene was purchased from The RNAi Consortium (TRC). Each shRNA was evaluated using Western blot analysis (data is not shown). The most efficient shRNA for each gene was chosen for further investigation. MCF-7 cells were transiently transfected with PPARy and MAZ shR-NAs, as well as with a scrambled shRNA as control. MCF-7 cells treated only with the transfection reagent were also used as a control. To evaluate the specificity of shRNAs to their target genes and the extent of PPARy1 down-regulation when either PPARy or MAZ shRNA were applied to MCF-7 cells, Real-time PCR, Western blot analysis and Luciferase assay were performed. Real-time PCR data revealed that both PPARy and MAZ shRNAs are highly specific to their targets and their application to the cells leads to a significant decrease in PPARy1 or MAZ mRNA levels respectively (Fig. 2A). We also tested whether the observed changes in PPARy1 or MAZ mRNA lead to changes in PPAR₇1 protein expression. Figure 2B shows

the representative immunoblot for PPARγ1 and demonstrates the level of PPARγ1 down-regulation by both PPARγ and MAZ shRNAs as compared to controls. The statistical evaluation of three different Western blots showed that the direct inhibition of PPARγ1 by PPARγ shRNA resulted in an average 50 percent decrease in PPARγ1 expression. A lower level of inhibition was observed when PPARγ1 knocked-down was achieved via down-regulation of MAZ expression. This was anticipated since we believe transcription factors other than MAZ are involved in regulation of PPARγ1 in cancer cells.

It is known that PPARy activates gene transcription by interacting with a Peroxisome-Proliferator Response Element (PPRE) located within the promoter sequence of target genes [2]. To confirm that shRNAs-mediated downregulation not only affects expression but also activity of PPARy1, a PPRE functional response was measured. MCF-7 cells were transfected with a 3XPPRE-mTK-pGL3 reporter plasmid and then co-transfected with scrambled, PPARy, or MAZ shRNA expression plasmids. Following transfection, cells were treated with 10 µM Rosiglitazone (Rosi), a well known PPARy agonist [39]. Cells were lysed 24 hours after the second transfection and a Luciferase assay was performed. Data demonstrated that direct down-regulation of PPARy1 expression by PPARy shRNA led to a significant decrease in PPRE-mediated reporter activity in both Rosi treated and untreated MCF-7 cells (Fig. 2C). This confirms that PPARy shRNA is specific and efficient for the inhibition of PPARy1 expression and activity. Moreover, the fact that PPRE activity falls below the control level when PPARy shRNA is applied to the cells is additional evidence for endogenous transactivation of PPARy1 in breast cancer cells. Although we observed a decrease in reporter activation when MAZ shRNA was transfected to the cells, these changes were not statistically significant, suggesting the complexity of PPARy transcriptional regulation and that the knock-down of MAZ seen in transient transfection assays is not sufficient to block PPRE-mediated reporter activity.

Down-regulation of PPAR γ I expression by PPAR γ or MAZ shRNA decreases proliferation of MCF-7 breast cancer cells

Since one of the most important characteristics of tumor development is enhanced cell growth, we tested whether inhibition of PPARγ1 expression affects cellular proliferation in breast cancer cells. MCF-7 cells were transiently transfected with scrambled, PPARγ, or MAZ shRNA and the rate of BrdU incorporation during DNA synthesis was assessed by using the BrdU proliferation assay (Roche). The results revealed that down-regulation of PPARγ1 by both PPARγ and MAZ shRNAs significantly decreased cellular proliferation in MCF-7 breast cancer cells (Fig. 3A). To confirm these results, we used a different approach to




Figure I PPAR γ **I** is over-expressed in various breast cancer cell lines as compared to HMEC. A. The representative Western blot of PPAR γ I expression. Whole cell lysates (40 μg of total protein) from nine different cell lines were analyzed by Western blot analysis as described in the methods section. **B.** Densitometry was used to quantify PPAR γ I expression. The chart represents data from the three different immunoblots (n = 3). Intensity of each band was normalized to actin. PPAR γ I expression is shown as a fold change in band intensity relative to HMEC. Statistical analysis was performed and demonstrated a significant difference in PPAR γ I expression in all tested cancer cell lines as compared to HMEC (p < 0.05).




Figure 2 Effect of PPAR γ and MAZ shRNAs applications on down-regulation of PPAR γ I expression and activity in the MCF-7 breast cancer cell line. A. To test the specificity of MAZ and PPAR γ shRNAs for their target genes and estimate the efficiency of MAZ and PPAR γ knock-down, Real-time PCR analysis of MCF-7 cells transfected with scrambled, MAZ, or PPAR γ shRNA was performed. The fold change in gene expression was calculated using the ΔΔCt method. I8S was included as an internal control.B. Representative Western blot analysis of PPAR γ I expression in MCF-7 cells transiently transfected with scrambled, MAZ, or PPAR γ shRNA. Densitometry was used to quantify PPAR γ I expression (n = 3). PPAR γ I expression is shown as a fold change in band intensity relative to control MCF-7 cells. Intensity of each band was normalized to actin. C. PPRE-mediated reporter activity was measured in MCF-7 cells transiently transfected with a 3XPPRE-mTK-pGL3 reporter plasmid and then co-transfected with MAZ or PPAR γ shRNA expression plasmids. Cells were also subsequently treated with 10 μM Rosi for 20 hours. Data is expressed as mean fold change in luciferase to renilla ratios compared to control.

inhibit endogenous activity of PPARy1. MCF-7 cells were transiently transfected with a vector driving the expression of a dominant-negative mutant of PPARy, $\Delta 462$, or an empty vector as control, and then a BrdU proliferation assay was performed. Inhibition of endogenous PPARy1 activity using the Δ462 mutant caused a decrease in cellular proliferation in MCF-7 cancer cells (Fig. 3B). To test whether endogenous activation of PPARy1 plays a similar role in other types of breast cancer cells, the same experiment was performed using the breast cancer cell line, T47D. The level of PPARγ1 expression in this cell line was evaluated using Western blot analysis (Fig. 3D). T47D cancer cells were transiently transfected with either a control vector or a Δ462 expression vector and then a BrdU proliferation assay was performed. Inhibition of PPARy1 activity in these cells also led to a significant decrease in cellular proliferation (Fig. 3C). To confirm that the observed changes in cellular proliferation in both MCF-7 and T47D cell lines are indeed in response to the inhibition of PPARy1 activity in a dominant-negative manner by Δ462, a Luciferase assay was performed. Cells were transfected with 3XPPRE-mTK-pGL3 reporter plasmid and then co-transfected with control or $\Delta 462$ expression plasmids. Following transfection, cells were treated with 10 μM Rosi. In Rosi treated and untreated cells, application of a $\Delta 462$ mutant resulted in a significantly lower level of PPRE-mediated reporter activity (Fig. 3E), thus, demonstrating that $\Delta 462$ efficiently inhibits endogenous activity of PPARy1 in MCF-7 and T47D cancer cells.

Down-regulation of PPARyI gene expression affects cell cycle distribution by decreasing the number of cells entering S-phase in MCF-7 cells

To elucidate the mechanism by which down-regulation of PPAR γ 1 expression leads to inhibition of cellular proliferation in MCF-7 cells, fluorescence-activated cell sorting (FACS) was performed. Analysis of cell cycle distribution (Fig. 4) revealed that PPAR γ 1 down-regulation by PPAR γ 0 or MAZ shRNA primarily affects cell transition from G₁ to S-phase in MCF-7 cells. Approximately 25 percent fewer cells entered the S-phase when PPAR γ 1 expression was suppressed directly or indirectly. This is consistent with data from the BrdU proliferation assay. Therefore, these results confirm our hypothesis and demonstrate that an increase in PPAR γ 1 expression and its endogenous transactivation play an important functional role in promoting cellular proliferation in breast cancer cells.

FACS analysis allowed us to assess changes in apoptosis as well. Interestingly, the level of apoptosis (Fig. 4D) and the percentage of debris and aggregates (data not shown) in cells transfected with either PPAR γ or MAZ shRNA was significantly higher than in control cells or scrambled shRNA transfected cells. This observation suggests that in addition to its involvement in regulation of proliferation,

PPAR γ 1 may also be involved in regulation of apoptosis in MCF-7 cells.

Down-regulation of PPAR γ I gene expression increases apoptosis in MCF-7 breast cancer cells

To evaluate data from FACS analysis (Fig. 4D) and determine whether changes in PPARy1 expression can affect apoptosis, a Cell Death Detection ELISA assay was performed which distinguishes between necrotic and apoptotic cell death. MCF-7 cells were transfected with scrambled, PPARy, or MAZ shRNA using the same transfection protocol and time points as for the proliferation assay, FACS, and protein analysis. The results showed no significant difference in necrotic cell death between PPARy knock-down and control cells (data not shown). However, inhibition of PPARy1 expression in MCF-7 cells using PPARy or MAZ shRNA resulted in a significant increase in apoptosis as compared to control (Fig. 5A). Interestingly, changes caused by down-regulation of PPARy1 directly by using PPARy shRNA were more dramatic than through knock-down of MAZ. This suggests that MAZ probably contributes to regulation of apoptosis mostly through its mediation of PPARy1 signaling in cancer cells. To confirm that down-regulation of PPARy1 expression induces apoptosis, the expression of Bcl2, an anti-apoptotic protein, which has been shown to promote the survival of cancer cells [40] was evaluated. Statistical analysis of densitometry for four Western blots demonstrated that Bcl2 expression was significantly higher in control and MCF-7 cells transfected with scrambled shRNA versus cells transfected with PPARy or MAZ shRNA (Fig. 5B). We also assessed changes in poly (ADP-ribose) polymerase-1, PARP-1, cleavage in cells transfected with PPARy or MAZ shRNA as compared to controls. PARP-1 cleavage by caspases is a well-known marker for apoptosis [41]. Statistical evaluation of densitometry for three Western blots (Fig. 5C) showed a significant increase in an 89 kDa C-terminal fragment, the product of PARP-1 proteolysis, when PPARy shRNA was applied to MCF-7 cells. This data suggests that an increase in PPARy1 expression followed by transactivation during cancer development may be an important factor that contributes not only to acceleration of cellular proliferation but also to cell evasion from apoptosis.

Discussion

In this report, we confirmed that PPARγ1 is highly expressed in cultured breast cancer cell lines as compared to HMEC [37,42]. High expression of PPARγ1 has also been reported in human breast cancer tissues [43]. However, questions about the mechanism and role of endogenous transactivation of PPARγ1 during development of breast cancer still remain unanswered. We have previously shown that the increase in expression of PPARγ1 from normal human mammary epithelia to breast cancer is due






Figure 3 Decreased PPARγ**I** expression is associated with a less proliferative phenotype for MCF-7 cells. **A**. Cell proliferation of MCF-7 cells transfected with or without scrambled, MAZ, or PPARγI shRNA was measured based on incorporation of the pyrimidine analog BrdU into DNA (BrdU proliferation ELISA). Data is shown as mean fold changes in cell proliferation compared to control cells. Error bars represent the standard error of the mean (s.e.m.) and the bars that do not share a letter designation were determined to be significantly different by Tukey's pairwise comparison (p < 0.05). **B**. MCF-7 cells were transiently transfected with a Δ462 expression plasmid. Cell proliferation was measured by BrdU proliferation was measured by BrdU proliferation transfected with a Δ462 expression plasmid or control plasmid. Cell proliferation was measured by BrdU proliferation ELISA. In Fig. B and Fig. C Student's t-test showed a significant difference (p < 0.01). **D**. The level of PPARγI expression in HMEC, MCF-7, and T47D cells was determined using Western blot analysis. Densitometry was used to quantify PPARγI expression in MCF-7 and T47D (n = 3). PPARγI expression in T47D is shown as a fold change in band intensity relative to MCF-7 cells. Intensity of each band was normalized to actin. **E**. PPRE-mediated reporter activity was measured by Luciferase assay in MCF-7 and T47D cells transfected with a dominant-negative mutant, Δ 462, or control plasmid. Cells were also subsequently treated with 10 μM Rosi for 20 hours. Data is shown as mean fold change in cell proliferation compared to control cells. Error bars represent the standard error of the mean (s.e.m.). * Significantly different from appropriate control at p < 0.01.


to the recruitment of a distal, tumor-specific promoter [34]. We identified MAZ as a transcription factor that directly binds to this promoter and drives expression of PPARγ1 in MCF-7 breast cancer cells [37]. Our results also indicated that MAZ is highly expressed in MCF-7 cells as compared to HMEC [36]. In this study, statistical analysis of three different Western Blots demonstrated an increase in PPARγ1 expression in a panel of different breast cancer lines and confirmed that it is a feature attributed not only to MCF-7 cells but also to other tested breast cancer cell lines. This observation suggests that the proposed model of endogenous PPARγ1 transactivation may apply not

only to a particular cell line, but also to breast cancer in general. Currently this hypothesis is being tested in the lab using pathological sections from normal and breast cancer specimens.

In efforts to explore the role of PPARγ activation in cancer, most of the recent studies employed pharmacological approaches. The anti-cancer activity of PPARγ ligands, such as TZDs, demonstrated in multiple *in vitro* studies, has raised discussion about the possibility of using PPARγ receptors as a target for breast cancer therapy. However, the "off target" effects of PPARγ agonists [44,45], the dual










Figure 4 Down-regulation of PPARγ**I or expression of MAZ prevents S-phase entry in MCF-7 breast cancer cells.**Changes in cell cycle distribution of MCF-7 cells transfected with or without scrambled, MAZ, or PPARγI shRNA were analyzed by FACS. Cells were stained with propidium iodide (PI). Mean and s.e.m. from five independent experiments are shown. Error bars that do not share a letter designation were determined to be significantly different by Fisher's LSD pairwise comparison (p < 0.05). **A.** Inhibition of PPARγI or MAZ expression leads to a decrease in a number of cells entering S-phase. **B.** A decrease in the number of proliferating cells in PPARγI or MAZ shRNA transfected cells is associated with an increase in the number of G_0 - G_1 arrested cells. **C.** There was no significant difference in M- G_2 phase cell number observed among all groups. **D.** Down-regulation of PPARγI as well as MAZ leads to an increase in the number of apoptotic cells.

role that some ligands play when they are applied to the cells at different concentrations [46], and the paradoxical anti-cancer effect of PPAR γ antagonists [47] necessitated the use of other approaches to evaluate the consequences of PPAR γ transactivation in cancer. For the first time, using an *in vitro* model, we have addressed questions about the role that endogenous transactivation of PPAR γ 1 plays in the pathogenesis of breast cancer. Using RNAi techniques

to inhibit PPAR γ 1 expression we demonstrated that an increase in PPAR γ 1 signaling can significantly affect proliferation and apoptosis in breast cancer cells. It is widely accepted that the dysfunctional balance between cellular proliferation and apoptosis can contribute to the initiation and progression of cancer. Here, we demonstrated that down-regulation of PPAR γ 1, directly or indirectly via knock-down of its transcriptional regulator MAZ, leads to




Figure 5 Down-regulation of PPARγ**I increases apoptosis in MCF-7 breast cancer cells. A**. Apoptosis was measured by specific determination of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates from control and shRNA transfected MCF-7 cells. Data is shown as mean fold changes in cell apoptosis compared to control. Error bars represent s.e.m. and the bars that do not share a letter designation were determined to be significantly different by Tukey's pairwise comparison (p < 0.05). **B**. Representative Western blot analysis of PPARγI and Bcl2 expression in control and shRNA transfected MCF-7 cells showed that a decrease in PPARγI expression leads to a decrease in Bcl2 expression. Densitometry was used to quantify Bcl2 expression (n = 4). Bcl2 expression is shown as a fold change in band intensity relative to control MCF-7 cells. Intensity of each band was normalized to actin. **C**. Western blot analysis of PARP-I demonstrated an increase in induction of PARP-I cleavage in MCF-7 cells transfected with PPARγI shRNA. Densitometry was used to quantify an 89 kDa fragment of PARP-I cleavage (n = 3). It is shown as a fold change in the 89 kDa band intensity relative to control MCF-7 cells. Intensity of each band was normalized to actin. * Significantly different from control at p < 0.05.

a decrease in cellular proliferation in MCF-7 breast cancer cells. Interestingly, changes in cellular proliferation caused by direct PPAR γ 1 inhibition by PPAR γ shRNA were analogous to changes in PPAR γ 1 expression when inhibited via down-regulation of MAZ. This suggests that in addition to its role as a mediator of tumor-specific expression of PPAR γ 1, MAZ may also be involved in the regulation of other growth control genes in MCF-7 breast cancer cells. The ongoing project in our lab is to further investigate the role of MAZ in breast cancer development.

The observed pro-survival effect of PPARy1 signaling in MCF-7 cancer cells was also confirmed by using a different approach to inhibit endogenous activity of PPARy1. We took advantage of a PPARγ1 mutant, Δ462, which lacks helix12, critical for ligand binding and co-activators recruitment. Thus, Δ462 functions in a dominant-negative manner. Data from BrdU proliferation assays demonstrated that inhibition of PPARγ1 activity using Δ462 decreases cell proliferation not only in MCF-7 cells but in another widely studied breast cancer cell line, T47D. In our previous study, we have shown that the T47D cell line also has a functional peroxisomal response [42]. Here, using Western blot analysis, we demonstrated that T47D cancer cells as well as MCF-7cells have high level of PPARy1 expression as compared to HMEC. However, the direct comparison of PPARy1 expression in MCF-7 and T47D cells showed the lower level of PPARγ1 in a latter cell line. The differential expression of PPARy1 in these cell lines can explain the more prominent changes in cellular proliferation in MCF-7 cells compare to T47D cells when $\triangle 462$ are applied to the cells. The specificity of $\triangle 462$ in the inhibition of endogenous PPARy1 activity was confirmed using Luciferase assay. We measured PPRE-mediated reporter activity when either MCF-7 or T47D cells were transfected with $\Delta 462$ or control plasmids and then treated with 10 µM Rosi. Data revealed that PPRE reporter activity is significantly lower in cells transfected with the Δ462 expression plasmid compared to control, thus, providing the evidence that this mutant acts in dominantnegative manner, decreasing activity of PPARy1 in MCF-7 and T47D cancer cells. Moreover, a similar effect was observed with Rosi, confirming the specificity of $\Delta 462$ action in these cell lines. In summary, these results suggest that PPARy1 transactivation enhances cell growth in breast cancer cells and that this phenomenon is not specific to MCF-7 cells.

To further investigate the mechanism by which PPAR γ 1 regulates cell growth, we performed fluorescence-activated cell sorting (FACS). Cell cycle distribution analysis confirmed results from the BrdU proliferation assay and demonstrated that an increase in PPAR γ 1 signaling accelerates the transition of cells from G₁-phase to S-phase and, thus, increases cellular proliferation.

Blockage of apoptosis is a likely requirement for cancer maintenance [48]. In fact, FACS analysis revealed that the number of cells which undergo apoptosis is much higher in MCF-7 cells with decreased PPARy1 expression. This observation was tested and confirmed by measuring DNA fragmentation in control and PPARy or MAZ shRNA transfected cells. The data demonstrated that down-regulation of PPARy1 expression in MCF-7 cells leads to a significant increase in apoptosis. The induction of apoptosis in cells with PPARγ1 or MAZ knockdown was also confirmed by analyzing the expression of Bcl2, a protein that is known to block cell death [40], and by evaluation of PARP-1 cleavage, a widely accepted marker for apoptosis. The results showed that inhibition of PPARy1 leads to downregulation of Bcl2 which may in turn favor re-activation of signaling pathways to induce apoptosis. The increase in PARP-1 cleavage in MCF-7 cells, which have a decreased level of PPARy1 expression, verified the induction of apoptosis as well. Together these results suggest that accelerated PPARy1 signaling can interfere with apoptotic pathways and promote cancer cell survival during breast tumor development. However, the molecular mechanisms that drive these events are not known and will be the subject of future investigation in the lab.

In summary, this study demonstrates that the increase in PPARy1 expression observed in breast cancer results in an increase in PPARy1 signaling that in turn promotes proliferation and inhibits apoptosis and thus, may significantly contribute to the progression of disease to a more malignant stage. Our findings are consistent with results from a study that evaluated the consequences of intrinsic PPARy1 activation using transgenic mice. This study demonstrated that constitutive over-expression of PPARy1 in mice, which were predisposed to breast cancer, leads to a greater number of tumors and higher mortality in both male and female animals, thus suggesting that increased PPARy1 signaling serves as a tumor promoter in the mammary gland [31]. Since constitutive PPARy1 signaling did not affect mammary gland differentiation or function when introduced in wild-type mice, the authors emphasized that consequences of PPARy1 transactivation are different in normal and transformed cells. This observation is consistent with our previous data, which demonstrated different mechanisms of transcriptional regulation of PPARy1 in breast cancer cells as compared to HMEC [34,37].

Conclusion

This study provides insight into the functional significance of increased PPARγ1 expression and endogenous transactivation in breast cancer in an *in vitro* model. The results suggest that increased PPARγ signaling can act as a pro-survival factor by enhancing cancer cell proliferation and blocking the ability of the cell to undergo apoptosis. Furthermore, modulation of the PPARγ1 signaling path-

way remains a promising tool for breast cancer therapy. The findings presented in this paper warrant further investigation regarding the use of PPAR γ 1 ligands, such as TZDs, in patients who are predisposed or already diagnosed with breast cancer. However, more broad and detailed studies are required to evaluate the impact of PPAR γ 1 signaling in breast cancer progression.

Methods Cell culture

MCF-7 and T47D breast cancer cells were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in modified DMEM (Gibco BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (Hyclone). Normal human mammary epithelial cells (HMEC) (Cambrex) were cultured in MEGM® with SingleQuot® supplements. All cell lines were grown in media lacking phenol red at 37°C in a 5% CO₂ atmosphere.

Western blot analysis

The whole cell lysates were prepared using passive lysis buffer. Concentrations were determined using a Bradford Assay (BioRad). 30 µg of total cell lysate per sample was run on a 10% or 12% SDS polyacrylamide gel. The proteins were transferred to a nitrocellulose membrane, blocked in 5% TBST, and incubated at 4°C overnight with primary antibody. The membrane was then washed and incubated for 4 hours with secondary IgG-HRP antibody. After incubation the membrane was washed, incubated with Chemiluminescence substrate (Pierce) for 5 min, and expose to film. The following primary antibodies were used: PPARy mouse monoclonal IgG antibody 1:200 dilution (Santa Cruz Biotechnology, sc-7273), Bcl2 mouse monoclonal antibody 1:1000 dilution (Santa Cruz Biotechnology, sc-509), PARP-1 rabbit polyclonal antibody 1:1000 dilution (Santa Cruz Biotechnology, sc-2578). Appropriate secondary goat anti-mouse (Santa Cruz Biotechnology, sc-2055), or bovine anti-goat (Santa Cruz Biotechnology, sc-2378), or goat anti-rabbit secondary antibody 1:1000 dilution (Santa Cruz Biotechnology, sc-2004) antibodies 1:1000 dilution were applied. Antiactin raised in rabbit 1:2000 dilution (Sigma, A 5060) and goat anti-rabbit secondary antibody 1:1000 dilution (Santa Cruz Biotechnology, sc-2004) were used to visualize actin. Western Blot Stripping Buffer (Pierce, # 21059) was used to restore membranes.

shRNAs constructs

The set of five shRNAs for PPARγ1 (TRCN 0000001670-74) and MAZ (TRCN 0000015343-47) genes as well as scrambled shRNA and non-hairpin TRC controls were purchased from The RNAi consortium (TRC) Human shRNA Library (Open Biosystems). The shRNA construct includes a hairpin of 21 base pairs, a sense and antisense

stem, and a 6 base-pair loop. Each hairpin sequence is cloned into a lentoviral vector (pLKo1). Based on structural evaluation and Western blot analysis the most efficient shRNAs for PPAR γ 1 (TRCN 0000001672) and MAZ (TRCN 0000015345) were chosen for transient transfections.

Dominant-negative PPARyI construct

The dominant-negative PPARγ1 mutant was a kind gift of Dr. Stephen O'Rahilly and Dr. V. Krishna K Chatterjee, Department of Medicine, Addenbrook's Hospital, Cambridge, U.K. Sequence analysis revealed a single base deletion introducing a premature stop codon (5'-₁₃₈₀ GACAGACTGA₁₃₉₀-3') leading to translation of protein truncated just before the AF-2 domain.

Transfection assays

Cells were transiently transfected with 3.6 μ g of pGL3 plasmid containing 3XPPRE-mTK-Luc and Renilla (Allred, 2005) per 24-well plate and then co-transfected with scrambled, PPAR γ or MAZ shRNAs, Δ 462, or control plasmids using FuGENE transfection reagent (Roche). 4 hours after transfection cells were subsequently treated with 10 μ M Rosi for 20 hours. Cells were lysed in 80 μ l of passive lysis buffer and treated according to manufacture's instructions (Promega dual luciferase assay kit). Luminometry was performed on a Berthold Technologies Lumat 9507 (Wildbad, Germany). Results were calculated as raw Luciferase units divided by raw Renilla units (RLU's). Data is presented as mean fold changes in treated cells as compared to control cells.

Real-time PCR

Total mRNA was isolated using an RNeasy Mini Kit (Qiagen, CA) according to manufactures instructions. Real-time PCR was performed on total RNA using the TaqMan One-Step RT-PCR Master Mix Reagents Kit (Applied Biosystems). The pre-optimized primers and probes for MAZ, PPAR γ 1, and 18S were purchased from Applied Biosystems.

BrdU proliferation assay

MCF-7 cells were seeded at 0.1×10^4 cells/well in 96-well tissue culture plates. Cells were transiently transfected on the second and third day using $0.05~\mu g$ of plasmid and $0.3~\mu l$ of FuGENE 6 transfection reagent (Roche) per well. Control MCF-7 cells were treated with FuGENE6 only. 16 wells per each shRNA and control were used. The same experimental set-up was used when cells were transfected with a dominant-negative form of PPAR $\gamma 1$, $\Delta 462$. The media was changed before the second transfection. Cell Proliferation ELISA, BrdU (colometric) (Roche) was performed on the fifth day according to the manufacture instructions.

Apoptosis assay

The same protocol as for the proliferation assay was used to plate and transfect MCF-7 cells. A Cell Death Detection ELISA (Roche) was performed on the fifth day. The assay is based on quantitative sandwich-enzyme-immunoassay-principle and uses mouse monoclonal antibodies directed against DNA and histones. Cells were lysed in a 96-well plate, centrifuged, and 20 µl of supernatant was transferred into streptavidin-coated wells. A mixture of antibodies was added and the plate was then incubated for 2 hours. The unbound components were removed by washing. ABTS substrate was added and the amount of monoand oligonucleosomes were measured photometrically using the ELISA-plate reader according manufacture instructions (Roche).

Cell cycle analysis

The DNA content of control and shRNAs transfected MCF-7 cells was analyzed using a detergent-trypsin method (Vindelov, 1983). MCF-7 cells were seeded at 1×10^6 cells in 100 mm culture plates. Cells were transiently transfected on the second and third day with 6 μg of plasmid using 18 μl of FuGENE6 transfection reagent (Roche). On the fifth day the propidium iodide labeling procedure and fluorescence-activated cell sorting (FACS) using Mod FitLT V.3.1 software was performed (University of Kentucky Flow Cytometry Facility).

Statistics

Data was analyzed by a two-way analysis of variance (ANOVA) using the StatServer 6.1 (Insightful, Seattle, WA) from the server maintained by the University of Kentucky's Department of Statistics. In every 2-way ANOVA, Tukey's pair-wise comparison test was used post-hoc. P-values of less than 0.05 were considered to be significant. One-way ANOVA with Fisher's LSD or Tukey's pair-wise comparison post-hoc test were also used where appropriate. When appropriate, Student's t-test was also used for data analysis on Microsoft Excel.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors significantly contributed in the design of the study, data interpretation, and manuscript drafts. YYZ carried out all experiments. RCS performed all statistical analyses and figure design. NKW and XW assisted with $\Delta 462$ and PPRE-Luciferase experiments. MWK coordinated this study.

Acknowledgements

We would like to thank Linah Al-Alem and Dr. Dominique Talbert for their critical evaluation and review of our work. We also appreciate the assistance with experimental design and statistical analysis from Dr. Arnold

Stromberg from the University of Kentucky Department of Statistics. This work was supported by grants CA95609 and NCRR-P20-RR1559 to MWK.

References

- Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007.
- Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272:18779-18789.
- Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
- Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
- Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T, et al.: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
- Mukherjee R, Jow L, Croston GE, Paterniti Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272:8071-8076.
- Nwankwo JO, Robbins ME: Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 2001, 64:241-245.
- Issemann I, Prince RA, Tugwood JD, Green S: The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 1993, 11:37-47.
- Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993, 90:2160-2164.
- Thoennes SR, Tate PL, Price TM, Kilgore MW: Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol Cell Endocrinol 2000, 160:67-73.
- Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM:
 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819.
- Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferatoractivated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996, 137:4189-4195.
- 13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). | Biol Chem 1995, 270:12953-12956
- tor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.

 14. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272:3406-3410.
- Houseknecht KL, Cole BM, Steele PJ: Peroxisome proliferatoractivated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002, 22:1-23.
- Burns KA, Heuvel JP Vanden: Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007, 1771:952-960.
- Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW:

- Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. *Proc Natl Acad Sci USA* 2000, **97:**10990-10995.
- Shen D, Deng C, Zhang M: Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J 2007, 83:414-419.
- Kim KY, Kim SS, Cheon HG: Differential anti-proliferative actions of peroxisome proliferator-activated receptorgamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol 2006, 72:530-540.
- Mehta RG, Williamson E, Patel MK, Koeffler HP: A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000, 92:418-423.
- 21. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: **Terminal differentiation of human breast cancer through PPAR gamma.** *Mol Cell* 1998, 1:465-470.
- Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ, Law RE: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001, 286:916-922.
- 23. Liu H, Zang C, Fenner MH, Possinger K, Elstner E: **PPARgamma** ligands and **ATRA** inhibit the invasion of human breast cancer cells in vitro. *Breast Cancer Res Treat* 2003, **79:**63-74.
- Panigrahy D, Huang S, Kieran MW, Kaipainen A: PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005, 4:687-693.
- 25. Abe A, Kiriyama Y, Hirano M, Miura T, Kamiya H, Harashima H, Tokumitsu Y: **Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma.** Eur J Pharmacol 2002, **436:**7-13.
- Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I: Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Res Treat 2008.
- Talbert DR, Allred CD, Zaytseva YY, Kilgore MW: Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 2008, 108:23-33.
- Burton JD, Goldenberg DM, Blumenthal RD: Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008, 2008:494161.
- Eİstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95:8806-8811.
- Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J: Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998, 4:1053-1057.
- 31. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM: **PPAR gamma signaling exacerbates mammary gland tumor development.**Genes Dev 2004, **18:**528-540.
- Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, Wagner KU, Hennighausen L: Loss of the peroxisome proliferationactivated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002, 277:17830-17835.
- Wang X, Southard RC, Kilgore MW: The increased expression of peroxisome proliferator-activated receptor-gammal in human breast cancer is mediated by selective promoter usage. Cancer Res 2004, 64:5592-5596.
- Allred CD, Kilgore MW: Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 2005, 235:21-29.
- Wang T, Xu J, Yu X, Yang R, Han ZC: Peroxisome proliferatoractivated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006, 58:1-14.

- Yee LD, Sabourin CL, Liu L, Li HM, Smith PJ, Seewaldt V, Kniss DA: Peroxisome proliferator-activated receptor gamma activation in human breast cancer. Int J Oncol 1999, 15:967-973.
- Wang X, Southard RC, Allred CD, Talbert DR, Wilson ME, Kilgore MW: MAZ drives tumor-specific expression of PPAR gamma

 in breast cancer cells. Breast Cancer Res Treat 2007, 111(1):103-111.
- Song J, Murakami H, Tsutsui H, Tang X, Matsumura M, Itakura K, Kanazawa I, Sun K, Yokoyama KK: Genomic organization and expression of a human gene for Myc-associated zinc finger protein (MAZ). 1 Biol Chem 1998. 273:20603-20614.
- protein (MAZ). J Biol Chem 1998, 273:20603-20614.
 39. Spiegelman BM: PPAR-gamma: adipogenic regulator and thia-zolidinedione receptor. Diabetes 1998, 47:507-514.
- 40. Huang Z: Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000, 19:6627-6631.
- Soldani C, Lazze MC, Bottone MG, Tognon G, Biggiogera M, Pellicciari CE, Scovassi Al: Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? Exp Cell Res 2001, 269:193-201.
- Kilgore MW, Tate PL, Rai S, Sengoku E, Price TM: MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol Cell Endocrinol 1997, 129:229-235.
- Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, Sugawara A, Ishida T, Ohuchi N, Sasano H: Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 2006, 13:233-250.
- 44. Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP: **15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells.** *J Lipid Res* 2002, **43:**1818-1828.
- Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL, Chen CS: Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005, 67:1342-1348.
- Clay CE, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, Chilton FH: Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001, 49:413-420.
- Seargent JM, Yates EA, Gill JH: GW a potent antagonist of PPAR-gamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 9662, 143:933-937.
- Letai AG: Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008, 8:121-132.

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp

